A general construct for FC-based disease monitoring in patients with IBD is shown in Figure 1 , which illustrates the 4 phases of disease monitoring. 1, 34 Repeated FC measures are used to longitudinally track changes in a patient's condition over time.
In phase I, IBD is suspected, but neither endoscopically confirmed nor treated. In phase II, induction therapy is introduced to achieve disease control, resulting in patient response. Phase III begins with disease remission with continuation of maintenance therapy. 8, 9 Risk of false-positive results (irritable bowel syndrome) and false-negative results (dissimulation) 10, 11 Easy to perform; noninvasive C-reactive protein Moderate [3] [4] [5] 12 Moderate Moderate High Late position in disease progression pathway [12] [13] [14] Risk of false-positive results (acute infections and other inflammatory conditions) and falsenegative results (normal C-reactive protein, despite active disease) 13 Quick result; but requires venepuncture FC Good 11, 12, [15] [16] [17] [18] Good Moderate High Rises quickly in case of relapse; falls rapidly with successful treatment 19 Risk of false-positive results 20, 21 Possible reluctance by patients for repeated stool collection. The goal of monitoring in this phase is to detect deviations from the target range, indicating the start of phase IV. In phase IV, therapy is adjusted to re-establish disease control and bring FC levels back to the target range. Given this background and clinical need for a standardized approach to noninvasive IBD monitoring, we performed a systematic review to evaluate whether FC monitoring could be used to detect imminent disease flares and sustained remission.
METHODS
Eligible studies were those that followed at least 10 patients with IBD in remission at baseline (monitoring phase III) and presented at least 2 consecutive FC measurements. We accepted FC test intervals between 2 weeks and 6 months.
Studies that did not report the use of a FC cutoff (either predefined or based on receiver operating characteristic curves) were excluded from analysis.
Identification and Selection of Studies
We searched for studies published in Medline, Embase, and the Cochrane Library. The search strategy for Medline was ("Leukocyte L1 Antigen Complex" [Mesh] or "calprotectin" [tw] or "calgranulin" [tw] ) and ("Inflammatory Bowel Diseases" [Mesh] or "inflammatory bowel disease" [tw] or "inflammatory bowel diseases" [tw] or "IBD" [tw] or "Crohn" [tw] or "Colitis" [tw] ). For Embase, we used ("calgranulin"/exp or "calprotectin"/exp) and ("enteritis"/exp or "inflammatory bowel disease"/exp or "inflammatory bowel diseases"/exp or "ibd" or "crohn" or "colitis"/exp). Congress abstract (n ¼ 53); patients had active disease at baseline (n ¼ 29); FC test interval out of desired range (,2 weeks or .6 months) (n ¼ 14); narrative review, editorial, letter to editor, or comment (n ¼ 7); FC test results within 6 months before relapse not reported (n ¼ 7); FC cutpoint not reported (n ¼ 3); language other than English (n ¼ 3); and less than 10 participants (n ¼ 2). A, adults; C, children; CD, Crohn's disease; HBI, Harvey-Bradshaw Index; IBD-U, IBD-unclassified; N, number of participants; (P)CDAI, (Pediatric) Crohn's disease activity index; PGA, physicians global assessment; (P)UCAI, (Pediatric) ulcerative colitis activity index; RCT, randomized controlled trial; SES-CD, simple endoscopic score for Crohn's disease; TNF, tumor necrosis factor; UC-DAI, ulcerative colitis disease activity index.
We restricted our search to studies published in English only. Duplicate articles were manually deleted using RefWorks. For further relevant studies, we checked the reference lists of identified articles. The first selection of studies was performed by 1 reviewer (A.H.) on the basis of title and abstract. The full article of each potentially eligible study was then obtained. Two authors (A.H. and P.v.R.) independently assessed full manuscripts against the predefined inclusion criteria. Any disagreements were resolved by discussion, and consensus was reached with the third author (K.T.P.).
Data Extraction and Management
The following characteristics were extracted from each selected study: name of the first author, year of publication, country of origin, journal, study design criteria (prospective versus retrospective design), sample size (the number of patients in follow-up), baseline characteristics (type of IBD and age group), FC test characteristics (including cutoffs tested), reference standard (endoscopy), other markers of disease activity used (including symptom-based clinical indices and C-reactive protein), prevalence of disease flares, and the number of true positives, true negatives, false positives, and false negatives. Pooling of data was greatly jeopardized because of heterogeneity between studies and was therefore not undertaken.
Assessment of Risk of Bias and Applicability Concerns
The study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) checklist included in systematic reviews. 35 In QUADAS, 4 key domains are rated for risk of bias and concerns regarding applicability to the review questions. The signaling questions in each domain were specifically tailored to our review questions (see Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B478). We did not calculate summary scores because their interpretation is problematic and potentially misleading. 36 
RESULTS
This review includes results of electronic searches up to April 21, 2016 . A total of 1719 articles were identified, of which, 193 were retrieved for full text review. Of these, 187 were excluded for not meeting the eligibility criteria. Six articles were included in the final analysis (Fig. 2) .
Study Characteristics
Study characteristics of included studies are presented in Table 2 . All studies were published in the most recent 3 years, and all except 1 were from European countries. Sample size varied between 49 and 181 patients. All except 1 study included adult patients only. 37 The mean proportion of patients experiencing a disease flare during the observation period was 33.3% (184 of 552; range, 27%-50%), and the total observation period was 10 to 18 months. All studies included patients with UC of which 1 followed patients with disease exclusively confined to the rectum. 41 Two studies also included patients with Crohn's disease. 37, 40 The time interval between consecutive FC tests varied between 1 and 3 months. One study compared control patients assigned to usual care with patients exposed to a FC-guided doseescalation scheme with oral 5-aminosalicylates. 39 For the sake of clarity, we excluded the intervention group from our analysis because the number of relapses in the intervention group was directly influenced by the therapeutic intervention.
Methodological Quality of Included Studies
The methodological quality of the included studies is summarized in Table 3 . All studies used a prospective design, enrolled patients with IBD in remission, used a commercially available FC assay, and tested FC during the initial remission period and periodically thereafter. One study used only clinical activity scores as reference standard instead of endoscopic evaluation. 37 In half of the studies, endoscopy was scheduled according to the protocol when relapse was suspected. 38, 40, 41 Differential verification was evident in 3 studies. 19, 39, 40 Substantial differences between studies were observed in clinical and endoscopic definitions of relapse and predefined FC cutoff levels. 
Findings

Prognostic Value of Repeated FC Measurements for Relapse and Sustained Remission
All patients included in the final analysis collected the first feces sample while in remission. Most individual studies showed that asymptomatic patients with FC levels moving out of the normal range on the next measurement had higher risk of relapse within the next 2 to 3 months. When FC was elevated, the probability of relapse increased from 53% to 83%, as is shown in Table 4 . 19, [38] [39] [40] [41] Consecutive normal FC values were associated with reduced risk of relapse, with 67% to 94% probability of remission in the next 2 to 3 months.
One study investigated the prognostic value of $2 consecutive measurements above the upper limit of normal, 19 whereas the others focussed on an upward trend of FC between 2 measurements. [37] [38] [39] [40] [41] As can be seen in Table 5 , the former strategy resulted in the highest probability of relapse.
Optimal FC Cutoff for Monitoring Disease Activity
Probabilities of relapse and remission varied between studies, partly because different FC cutoffs were used. Variation in FC cutoffs could not explain all the difference. Patient variation, study design, and type of FC assay may also have contributed to the heterogeneity of the test accuracy. Because of the limited number of studies included in this systematic review, we were not able to derive the ideal cutoff point.
DISCUSSION
In this systematic review, we evaluated the utility of FC monitoring to detect imminent flares in asymptomatic patients with IBD. We identified only 6 studies meeting our inclusion criteria. Data collection were done prospectively in consecutive series of mostly patients with UC with quiescent disease at baseline. We found that there was poor consistency of reference standard use and definition of relapse between the studies. Two consecutively elevated FC levels appeared to be the best predictor for relapse, but this was systematically investigated in only 1 study. 19 An upward trend of FC out of the normal range was also prognostic for relapse, albeit with a lower probability of relapse.
Comparison with Other Reviews
We report the first systematic review that investigates the prognostic value of repeated FC measurements in asymptomatic patients with IBD. To date, there have been 2 meta-analyses of the diagnostic accuracy of a single FC measurement in almost exclusively symptomatic patients with previously diagnosed UC or Crohn's disease. 12, 15 In these circumstances, symptom-based clinical indices and derangements in serological markers of inflammation would likely lead clinicians to intensify medical therapy. Inclusion of these studies may cause overestimation of the prognostic value of calprotectin relative to the practical situation, where a monitoring test is necessary to discriminate between those who Only control group included in this table. C, relapse defined as clinical relapse; C&E, relapse defined as both clinical relapse or endoscopic relapse; CI, confidence interval; E, relapse defined as endoscopic relapse.
have preclinical relapse and those with quiescent IBD. We moved away from single FC measurements that are read in isolation when relapse is suspected and focused on repeated FC measurements in asymptomatic patients to predict relapse. Based on our review, we found that FC levels start rising 2 to 3 months before a relapse becomes apparent, and therefore support the biological implausibility that a single FC measurement at baseline can predict the clinical course over a 12-month period, as was suggested in a meta-analysis by Mao et al. 42 Cutoff Levels Furthermore, we were not able to identify the best FC cutoff for monitoring purposes. Currently, there is no consensus among IBD experts about the range of FC associated with mucosal healing, indicating a need for prospective and randomized studies comparing monitoring strategies that vary in thresholds. Table 5 elaborates on the specific outcomes when FC monitoring strategy leads to effective adjustments in IBD therapy from a patient's perspective. The underlying assumption here is that FC monitoring serves to improve patient-centered outcomes, representing a proactive approach to detecting indolent disease activity. Of note, when adopting FC monitoring, key questions most relevant to decision making are whether the numbers of false negatives (missed cases with relapse) and false positives (cases without disease activity who may receive treatment intensification) are acceptable within the new monitoring paradigm.
Clinical Implications
.Emerging evidence suggest that FC monitoring has the potential to result in less missed cases of asymptomatic patients with IBD with ongoing mucosal-level inflammation. In particular, patients with IBD who underreport symptoms and pediatric patients requiring anesthesia for each endoscopic evaluation are 2 subsets of patients who may benefit from FC monitoring. From a patient's perspective, bowel preparation for colonoscopy, repeated anesthesia, and incurring indirect costs are practical and important considerations in favor of FC monitoring. In addition, FC monitoring may serve as a feedback tool for better patient engagement, facilitating self-management strategies of their chronic condition.
Although there is no consensus on the optimal frequency of calprotectin retesting and cutoffs for treatment intensification, the authors of this article routinely monitor children with IBD using an enzyme-linked immunosorbent assay (ELISA) allowing quantification. A practical cutoff range could be as follows: levels below 250 mg/g as indicative for disease remission (green), levels above 500 mg/g as indicative for disease flare (red), whereas levels between 250 and 500 mg/g indicating need for more frequent calprotectin monitoring (yellow), as shown in Figure 1 . This "traffic light" is currently being evaluated in a prospective multicenter telemonitoring program. 43 Future studies are needed to determine whether pre-emptive treatment intensification based on elevated FC levels will lead to long-term better patient outcomes, including reduction of hospitalizations, disability-associated costs, and loss of productivity. The first prospective trials with mesalamine dose GRADE recommends classifying each outcome as either "critical for decision making," "important but not critical for decision making," or "not-important."
intensification 39, 44, 45 and infliximab dose interval adjustment 46 have already been performed with promising results.
Methodological Limitations of the Review
Although the methodology to conduct a systematic review and meta-analysis of diagnostic research is developed to a certain extent, at least for dichotomized tests, the systematic evaluation of a monitoring test is not bound to consensus guidelines. Although the articles we selected had to meet high methodological standards, we acknowledge several limitations. Significant heterogeneity in disease spectrum, study endpoints, FC cutoff levels, and quality of reporting are potentially confounding factors that may affect interpretation of the data and conclusions. Also, we restricted our search to studies published in English only, leading to potential bias.
CONCLUSIONS
This systematic review shows that the relapsing and remitting nature of IBD becomes less unpredictable with proactive FC monitoring in clinical practice, allowing early recognition of relapse before overt symptoms (or symptom reporting). Although FC monitoring may represent a more proactive strategy for treatment modifications in a treat-to-target approach, more robust data are necessary to determine whether it will improve decisionmaking and patient-centered outcomes.
